Bhagiradha Chemicals & Industries Limited will conduct a group meeting with investors and analysts on September 25, 2026, starting at 12:30 pm. The interaction is scheduled to take place at the company's wholly owned subsidiary, Bheema Fine Chemicals Plant, located in the Kadechur Industrial Area of Yadgir District, Karnataka.

The company informed BSE and NSE that discussions during the meeting will be strictly based on publicly available information. Officials stated that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions.

Meeting Details

The event is structured as a group meeting for participants including institutional investors and equity research analysts. The specific logistical details are outlined below:

Regulatory Compliance

This intimation is submitted pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that changes to the schedule may occur due to exigencies on the part of the participants or the company itself. A copy of the disclosure is available on the company's website for public reference.

Bhagiradha Chemicals & Industries delivered its highest-ever quarterly performance in Q1FY27, reporting a 235% year-on-year surge in net profit after tax (PAT) to ₹13.3 crore. The company’s revenue from operations climbed 58% to ₹195.0 crore, driven by robust volume growth, improved realizations, and a favorable product mix that included the launch of four new molecules in the mid- to high-value segments.

The filing, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was signed by Sharanya M., Company Secretary & Compliance Officer, on August 06, 2026. The presentation highlights a significant expansion in operating leverage, with EBITDA jumping 240% to ₹30.5 crore and gross profit rising 81% to ₹75.2 crore compared to Q1FY26.

Financial Highlights

The consolidated financial results for the quarter ended June 30, 2026, reflect strong margin expansion across key metrics:

Gross profit margin expanded to 38.6% from 33.5% in the previous year, while EBITDA margin more than doubled to 15.7% from 7.3%. The PAT margin also improved significantly to 6.8% from 3.2% in Q1FY26.

Operational Drivers

A. Arvind Kumar, Executive Director & CEO, attributed the growth to higher volumes and better realizations. The company introduced four new molecules—Tembotrione, Tolfenpyrad, Thifluzamide, and Novaluron—during the quarter, which contributed meaningfully to the growth trajectory. Raw material prices remained broadly stable, although select crude-linked inputs saw increases due to geopolitical developments in West Asia.

The Bheema Fine Chemicals facility continued its ramp-up, with capacity utilization nearly doubling compared to Q4FY26. This subsidiary remains focused on mid- and high-value molecules. At the existing Bhagiradha facility, management is gradually reducing the share of low-margin products and redeploying capacity toward higher-margin offerings to improve revenue quality.

What the Numbers Show

The disproportionate rise in EBITDA (240%) relative to revenue growth (58%) indicates substantial operating leverage gained through portfolio optimization. By shifting capacity away from low-margin products and leveraging the ramp-up at Bheema Fine Chemicals, Bhagiradha Chemicals has successfully decoupled margin expansion from pure volume growth, signaling a structural improvement in profitability drivers for FY27.